Susai, Subash Raj; Healy, Colm; Mongan, David; Heurich, Meike; Byrne, Jonah F; Cannon, Mary; Cagney, Gerard; Wynne, Kieran; Markulev, Connie; Schäfer, Miriam R; Berger, Maximus; Mossaheb, Nilufar; Schlögelhofer, Monika; Smesny, Stefan; Hickie, Ian B; Berger, Gregor E; Chen, Eric Y H; de Haan, Lieuwe; Nieman, Dorien H; Nordentoft, Merete; ... (2022). Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational psychiatry, 12(1), p. 454. Nature Publishing Group 10.1038/s41398-022-02217-0
|
Text
s41398-022-02217-0.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis participants at baseline and 6-months follow-up were included. Plasma protein levels were quantified using mass spectrometry and erythrocyte omega-3 PUFA levels were quantified using gas chromatography. We examined the relationship between change in polyunsaturated PUFAs (between baseline and 6-month follow-up) and follow-up plasma proteins. Using mediation analysis, we investigated whether plasma proteins mediated the relationship between change in omega-3 PUFAs and clinical outcomes. A 6-months change in omega-3 PUFAs was associated with 24 plasma proteins at follow-up. Pathway analysis revealed the complement and coagulation pathway as the main biological pathway to be associated with change in omega-3 PUFAs. Moreover, complement and coagulation pathway proteins significantly mediated the relationship between change in omega-3 PUFAs and clinical outcome at follow-up. The inflammatory protein complement C5 and protein S100A9 negatively mediated the relationship between change in omega-3 PUFAs and positive symptom severity, while C5 positively mediated the relationship between change in omega-3 and functional outcome. The relationship between change in omega-3 PUFAs and cognition was positively mediated through coagulation factor V and complement protein C1QB. Our findings provide evidence for a longitudinal association of omega-3 PUFAs with complement and coagulation protein changes in the blood. Further, the results suggest that an increase in omega-3 PUFAs decreases symptom severity and improves cognition in the CHR state through modulating effects of complement and coagulation proteins.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy |
UniBE Contributor: |
Berger, Maximus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2158-3188 |
Publisher: |
Nature Publishing Group |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
31 Oct 2022 10:15 |
Last Modified: |
05 Dec 2022 16:27 |
Publisher DOI: |
10.1038/s41398-022-02217-0 |
PubMed ID: |
36307392 |
BORIS DOI: |
10.48350/174281 |
URI: |
https://boris.unibe.ch/id/eprint/174281 |
Actions (login required)
 |
Edit item |